UNDISCLOSED Lead Financial Advisor Infusion Specialty Therapies Business Unit Divested to ESTEVE January 2026
$91M Upfront + Up to $16.8M Contingent Payments Exclusive Financial Advisor U.S. Rights to Zubsolv® Divested to Dexcel Pharma USA December 2025